HHS has decided not to move forward with confirming a permanent National Institutes of Health director this year because there is too little time remaining in the current Congressional session. National Institutes for Neurological Disorders & Stroke Director Gerald Fischback, MD, had been selected by the Administration as a potential nominee for the position. Ruth Kirschstein, MD, has been acting director since the departure of Harold Varmus, MD, at the end of 1999
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth